Dr. Reddy’s Laboratories Limited (REDY) (Q1FY24)
Stock Performance – Dr. Reddy’s Laboratories’ stock price showed a volatile trend in the past 3-month period. It gave 7.23% returns during the period. The price increased by 26.22% in the past 1 year. The stock has a 52-week high of ₹5,989.70 and its 52-week low is ₹4,175.10.
In the past 3 years, the stock has given returns of 7.47%. REDY has a 50-day moving Avg. and 200-day moving Avg. of ₹5,655.42 and ₹4,961.07, respectively.
Revenue Performance – Revenue was Rs. 60.1bn, YoY growth of 36% and QoQ growth of 11% in Q1FY24. The growth was driven by North America, Emerging Markets and Europe.
The company has achieved significant milestones in its biosimilar business, with the recent acceptance for review of the Rituximab biosimilar application by key regulatory bodies including the FDA, EMA, and MHRA. This development highlights the company’s dedication to advancing its position in the biopharmaceutical market, reflecting a positive step towards expanding its product portfolio and reaching a wider patient base.
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10-Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals
– Price Performance
Stock Price Performance
No of Pages: 32
To download the previous quarter’s equity/report CLICK HERE
To Download other equity/reports CLICK HERE
Follow our LinkedIn page for more updates.